Teknova reported Q4 2025 total revenue of USD 10.0 million (+8.0%), including Lab Essentials revenue of USD 6.8 million and Clinical Solutions revenue of USD 2.7 million (+47.0%). Q4 gross profit was USD 3.2 million and gross margin was 32.5%. Q4 net loss was USD 4.8 million and adjusted EBITDA was negative USD 1.8 million; cash used in operating activities was USD 0.5 million and free cash flow was negative USD 0.8 million. For FY 2025, Teknova posted total revenue of USD 40.5 million (+7.0%), gross profit of USD 13.4 million and gross margin of 33.2%. FY net loss was USD 17.3 million and adjusted EBITDA was negative USD 6.7 million; cash used in operating activities was USD 8.6 million and free cash flow was negative USD 9.8 million. The company ended FY 2025 with total cash and short-term investments of USD 21.3 million and gross debt of USD 13.2 million. Teknova said it achieved 25.0% annual growth in the number of Clinical Solutions customers in 2025 and plans to increase investment in commercial capabilities, while guiding for FY 2026 revenue of USD 42.0 million to USD 44.0 million and free cash outflow of less than USD 10.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Teknova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261601PRIMZONEFULLFEED9662241) on February 26, 2026, and is solely responsible for the information contained therein.